Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07091630 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

A Study to Assess the Efficacy and Safety of Empasiprubart in Adults With CIDP

Study acronym: emnergize
StatusRecruiting
PhasePhase 3
Sponsorargenx
Started2025-09-16
View on ClinicalTrials.gov ↗

Amendment history

2026-09-24
Trial sites expanded: 82 → 85 locations
2026-08-20
Study Status, Contacts/Locations v10
Trial sites expanded: 78 → 82 locations
Trial sites expanded: 71 → 78 locations
2026-07-21
Study Status, Contacts/Locations v9
Trial sites expanded: 61 → 71 locations
2026-06-11
Study Status, Contacts/Locations v8
Trial sites expanded: 56 → 61 locations
2026-05-27
Study Status, Contacts/Locations v7
Trial sites expanded: 43 → 56 locations
2026-05-07
Study Status, Contacts/Locations v6
Trial sites expanded: 19 → 43 locations
2026-03-09
Study Status, Study Description, Contacts/Locations, References v5
Study sites14→19
2026-02-06
Study Status, Contacts/Locations v4
Study sites9→14
2026-01-07
Study Status, Contacts/Locations v3
Study sites2→9
2025-12-10
Study Status, Contacts/Locations v2
Study sites1→2
2025-10-02
Not Yet Recruiting→Recruiting Study Status, Oversight, Eligibility, Contacts/Locations v1
Trial statusNot Yet Recruiting→Recruiting
Start dateestimated 2025-09→confirmed 2025-09-16
Study sites0→1
Eligibility criteria+171 characters
[...] corticosteroids, immunoglobulins, PLEX, or FcRn inhibitors) Participants already receiving CIDP treatment will have to discontinue their CIDP treatment before first IMP administration and must be willing to switch to the study IMP Exclusion Criteria: Meets the criteria for possible CIDP bas [...]
2025-07-22
Original filing
Argenx
56 trials monitored
See 2 trials at risk
The main purpose of this study is to demonstrate the efficacy and safety of empasiprubart in adults with CIDP. The study consists of a part A where participants will either receive empasiprubart or placebo for 24 weeks (6 months). Following part A, participants will enter part B in which all participants will receive empasiprubart for 96 weeks (24 months). More information can be found here: https://clinicaltrials.argenx.com/emnergize
Trial Details
NCT Number NCT07091630
Lead Sponsor argenx
Conditions Chronic Inflammatory Demyelinating Polyneuropathy, CIDP, Chronic Inflammatory Demyelinating Polyradiculoneuropathy
Enrollment 160 participants
Start Date 2025-09-16
Primary Completion 2027-10-07 (estimated)
Study Completion 2031-01-23 (estimated)
Updated on ClinicalTrials.gov 2026-09-24